A Phase 2 interventional study of LP-003 Injection and Placebo of LP-003 in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), sponsored by Longbio Pharma. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Longbio Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.
Among the 46 studies in Nasal Polyps with a site in China, this one is the 14th largest by planned enrollment of the 43 interventional ones that give a count, is one of 10 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 11 of the 23 other live ones, and was the 37th registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
Bambusa Therapeutics · Sites in China
Ages 18–75 · Healthy volunteers
Tang-Du Hospital · Sites in China
Ages 18–65
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 15 · Phase 4 4
First in 2010; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 90 across the 43 interventional studies, 146 across the 3 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 46 have an industry lead sponsor. The 10 most frequent:
Longbio Pharma is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Longbio Pharma has 1 study filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
6 of the studies in Nasal Polyps with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT07107256Phase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps | 2027-03 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07313917Longbio PharmaA Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 2027-02-28 |
| NCT07755371AkesoA Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 46 studies in Nasal Polyps with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the treatment of participants with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to investigate its pharmacokinetic (PK), pharmacodynamic (PD) profiles, and immunogenicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Persistence of the following symptoms for ≥ 4 weeks prior to the screening/run-in period:
Participants report moderate to severe nasal congestion during the screening/run-in period and prior to randomization:
Exclusion Criteria:
Current or prior receipt of the following treatments:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous injection of LP-003 Injection at a dose of 300 mg once every 12 weeks.
Biological: LP-003 Injection
Participants will receive subcutaneous injection of LP-003 Injection at a dose of 450 mg once every 12 weeks.
Biological: LP-003 Injection
Participants will receive subcutaneous injection of placebo Injection once every 12 weeks.
Biological: Placebo of LP-003
s.c. injection, Q12W
s.c. injection, Q12W
Change from baseline in Nasal Polyps Score (NPS) at Week 24
NPS is a bilateral endoscopic assessment scale for nasal polyposis, where each nasal cavity is scored from 0 to 4. The total score is the sum of the left and right sides, ranging from 0 to 8, with higher scores indicating more severe nasal polyp disease.
Time frame: Week 24
Change from baseline in Nasal Congestion Score (NCS) at Week 24
The NCS is a patient-reported outcome measure using a 0-3 point Verbal Rating Scale (VRS). Patients rate their nasal congestion severity as 0 (no symptoms), 1 (mild symptoms), 2 (moderate symptoms), or 3 (severe symptoms). The total score ranges from 0 to 3, with higher scores indicating more severe nasal congestion.
Time frame: Week 24
Change from baseline in NPS at each assessment visit (excluding Week 24)
Time frame: Up to approximately 56 weeks
Percentage of participants with a ≥1-point improvement in NPS from baseline
Time frame: Up to approximately 56 weeks
Percentage of participants with a ≥2-point improvement in NPS from baseline
Time frame: Up to approximately 56 weeks
Change from baseline in NCS at each assessment visit (excluding Week 24)
Time frame: Up to approximately 56 weeks
Percentage of participants with a ≥1-point improvement in NCS from baseline
Time frame: Up to approximately 56 weeks
Change from baseline in Total Score of 22-Items Sinonasal Outcome Test (SNOT-22)
The SNOT-22 is a validated 22-items questionnaire to assess the impact of chronic rhinosinusitis on health-related quality of life (HRQoL) with a recall period of 2 weeks. There are 5 domains that could be described within SNOT-22, including nasal, ear, sleep, general and practical, and emotional; each domain was scored on a 6-category scale which ranged from 0: no problem to 5: problem as bad as it can be. The total score was the sum of response to each of the 22 questions and ranged from 0 (no disease) to 110 (worst disease), higher scores indicated worse HRQoL.
Time frame: Up to approximately 56 weeks
Incidence of adverse events (AEs)
Time frame: Up to approximately 56 weeks
Number of patients with anti-drug antibodies (ADA)
Time frame: Up to approximately 56 weeks
Serum concentrations of LP-003
Time frame: Up to approximately 56 weeks
Start is estimated for Jan 2026; primary completion for Feb 2027, 13 months later.
Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LP-003
Longbio Pharma